Frank Clyburn - 10 May 2021 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
EVP & Pres ? Human Health
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Frank Clyburn
Issuer symbol
MRK
Transactions as of
10 May 2021
Transactions value $
$-1,513,440
Form type
4
Filing time
11 May 2021, 14:41:06 UTC
Previous filing
04 Nov 2021
Next filing
02 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRK Common Stock Options Exercise $0 +19,324 +20.5% $0.000000 113,672 10 May 2021 Direct
transaction MRK Common Stock Sale $-1,513,440 -19,324 -17% $78.32 94,348 10 May 2021 Direct F1, F2
holding MRK Common Stock - 401(k) Plan 1,753 10 May 2021 By 401(k) F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -19,324 -50% $0.000000 19,323 10 May 2021 Common Stock 19,324 $44.98 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.27 to $78.42, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2 Holdings include shares acquired in dividend reinvestment transactions.
F3 Includes shares acquired and dividends earned through April 7, 2021 in the Merck U.S. Savings Plan, a 401(k) plan.
F4 The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.